London
· Delayed Price · Currency is GBP · Price in USD Arbutus Biopharma Company Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States.
Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19.
It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300.
The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015.
Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
| Country | Canada |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 73 |
| CEO | Michael McElhaugh |
Contact Details
Address: 701 Veterans Circle Warminster, British Columbia 18974 United States | |
| Phone | 267 469 0914 |
| Website | arbutusbio.com |
Stock Details
| Ticker Symbol | 0SGC |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael McElhaugh | Chief Executive Officer |
| David Hastings | Chief Financial Officer |
| Michael McElhaugh | Chief Operating Officer |
| Lisa Caperelli | Head of Investor Relations |